Hepion CEO Gary Stetz builds 5.7% stake
Rhea-AI Filing Summary
Hepion Pharmaceuticals, Inc. (HEPA) is the subject of a Schedule 13D reporting that director and interim Chief Executive Officer Gary Stetz beneficially owns 5,250,000 shares of Common Stock, representing 5.7% of the class, based on 90,219,317 shares outstanding as of August 10, 2026.
The beneficial ownership includes 2,000,000 shares issuable upon exercise of warrants. In 2026, Stetz purchased 1,250,000 shares for $50,000 and 2,000,000 shares plus a warrant for 2,000,000 shares for $100,000. The warrant is immediately exercisable at $0.06 per share, subject to a Beneficial Ownership Limitation. The stake is reported as acquired for investment purposes, and he may acquire additional shares over time.
Positive
- None.
Negative
- None.
Filing Explained
The filing states that Gary Stetz acquired the shares for investment purposes and has no plans or proposals concerning the matters listed in Item 4, while retaining the possibility of further stock acquisitions.
Key Figures
Beneficial ownership: 5,250,000 shares of Common Stock
Ownership percentage: 5.7%
Shares outstanding: 90,219,317 shares
+5 more
8 metrics
Beneficial ownership
5,250,000 shares of Common Stock
Shares beneficially owned by Gary Stetz
Ownership percentage
5.7%
Percent of Hepion Common Stock class represented by 5,250,000 shares
Shares outstanding
90,219,317 shares
Hepion Common Stock outstanding as of August 10, 2026
Aggregate purchase price
$150,000.00
Total purchase price for shares beneficially owned by Gary Stetz
April 21, 2026 purchase
1,250,000 shares for $50,000.00
Common Stock acquired under Securities Purchase Agreement dated April 21, 2026
July 31, 2026 purchase
2,000,000 shares and warrant for 2,000,000 shares for $100,000.00
Common Stock and warrant acquired under Securities Purchase Agreement dated July 31, 2026
Warrant shares
2,000,000 shares
Shares of Common Stock issuable upon exercise of warrant
Warrant exercise price
$0.06 per share
Exercise price of warrant held by Gary Stetz, subject to Beneficial Ownership Limitation
Key Terms
Schedule 13D, Beneficial Ownership Limitation, Securities Purchase Agreement, Sole Voting Power, +1 more
5 terms
Schedule 13D regulatory
"This Statement is being filed on behalf of Gary Stetz"
A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.
Beneficial Ownership Limitation regulatory
"The warrant is immediately exercisable at $0.06 per share, subject to the Beneficial Ownership Limitation"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
Securities Purchase Agreement financial
"pursuant to a Securities Purchase Agreement dated July 31, 2026 for an aggregate purchase price"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
Sole Voting Power regulatory
"Number of Shares Beneficially Owned by Each Reporting Person With: | 7 | Sole Voting Power"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
Sole Dispositive Power regulatory
"Number of Shares Beneficially Owned by Each Reporting Person With: | 9 | Sole Dispositive Power"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
FAQ
How much of Hepion Pharmaceuticals (HEPA) stock does Gary Stetz beneficially own?
Gary Stetz beneficially owns 5,250,000 shares of Hepion Pharmaceuticals Common Stock, representing 5.7% of the class, based on 90,219,317 shares outstanding as of August 10, 2026. His holdings include 2,000,000 shares issuable upon exercise of warrants.
What roles does Gary Stetz hold at Hepion Pharmaceuticals (HEPA)?
Gary Stetz is identified as a director and interim Chief Executive Officer of Hepion Pharmaceuticals, Inc. He is also the reporting person with respect to the disclosed beneficial ownership of the company’s Common Stock.
How much has Gary Stetz paid in total for his reported Hepion (HEPA) holdings?
The aggregate purchase price of the Hepion Common Stock beneficially owned by Gary Stetz is reported as approximately $150,000, consisting of a $50,000 purchase on April 21, 2026 and a $100,000 purchase on July 31, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
